Geisinger Medical Group

Summary

Geisinger Medical Group is a medical facility located in State College, Pennsylvania. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Ovarian Cancer, Non-Small Cell Lung Cancer and other specialties. Geisinger Medical Group is involved with conducting 190 clinical trials across 278 conditions. There are 11 research doctors associated with this hospital, such as Joseph J. Vadakara, Raghava Reddy Levaka Veera, Sorab Gupta, and Namita Sharma.

Top PIs

Clinical Trials running at Geisinger Medical Group

Lung Cancer

Non-Small Cell Lung Cancer

Multiple Myeloma

Meningioma

Sarcopenia

Colorectal Cancer

Squamous Cell Carcinoma

Breast cancer

No change needed.

HER2 Negative

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Osimertinib +/- Chemotherapy

for Lung Cancer

The goal of the study is to collect data on patients treated outside of a clinical trial (in routine clinical practice) with standard of care osimertinib with or without chemotherapy in Epidermal Growth Factor Receptor (EGFR)-mutant Non-Small Cell Lung Cancer (NSCLC) to better understand the safety and effectiveness of these standard of care regimens.

Recruiting

1 award

N/A

8 criteria